Yecuris adds value to pre-clinical drug development programs with our proprietary liver-humanized FRG® KO mouse technologies and related contract services. From tissue targeting to identifying off-target effects or modeling for multi-species preclinical development pathways, FRG provides utility for many gene editing and gene therapy programs. Whether you want mice with human hepatocytes harboring genetic and metabolic disorders or want in vivo cross-species comparisons with our new HepaSpecies™ xenograft service, Yecuris can help de-risk and advance your program.
Contact us today!